Cytocare Inc. (NASDAQ:CYTI) said that it has acquired exclusiveworldwide rights to diagnostic, prognostic and therapeutic usesof certain hybridoma cell lines and murine monoclonalantibodies specific for prostate cancer.
The patented molecules were licensed from the Sloan-KetteringInstitute for Cancer Research. Irvine, Calif.-based Cytocare isdeveloping a family of molecules to diagnose and treat benignprostatic hypertrophy and prostate cancer. The company'sshares closed unchanged at $1.88 on Tuesday.
(c) 1997 American Health Consultants. All rights reserved.